JP2024510436A5 - - Google Patents
Info
- Publication number
- JP2024510436A5 JP2024510436A5 JP2023554337A JP2023554337A JP2024510436A5 JP 2024510436 A5 JP2024510436 A5 JP 2024510436A5 JP 2023554337 A JP2023554337 A JP 2023554337A JP 2023554337 A JP2023554337 A JP 2023554337A JP 2024510436 A5 JP2024510436 A5 JP 2024510436A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- degrees
- approximately
- treatment
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163162501P | 2021-03-17 | 2021-03-17 | |
| US63/162,501 | 2021-03-17 | ||
| US202163284592P | 2021-11-30 | 2021-11-30 | |
| US63/284,592 | 2021-11-30 | ||
| PCT/US2022/020716 WO2022197901A1 (en) | 2021-03-17 | 2022-03-17 | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for the treatment of major depressive disorder |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024510436A JP2024510436A (ja) | 2024-03-07 |
| JP2024510436A5 true JP2024510436A5 (cg-RX-API-DMAC7.html) | 2025-03-25 |
Family
ID=81327141
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023554337A Pending JP2024510436A (ja) | 2021-03-17 | 2022-03-17 | 大うつ病性障害の処置のための19-ノルc3,3-2置換c21-n-ピラゾリルステロイド |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240245711A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4308162A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024510436A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230158033A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022238365A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023018607A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3213744A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL305858A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023010728A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202300156A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022197901A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS62761B1 (sr) | 2012-08-21 | 2022-01-31 | Sage Therapeutics Inc | Alopregnanolon za lečenje refraktornog epileptičkog statusa |
| SMT202100509T1 (it) | 2013-04-17 | 2021-11-12 | Sage Therapeutics Inc | Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| WO2016082789A1 (en) | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| WO2018013613A1 (en) | 2016-07-11 | 2018-01-18 | Sage Therapeutics, Inc. | C17, c20, and c21 substituted neuroactive steroids and their methods of use |
| TW202604538A (zh) | 2016-08-23 | 2026-02-01 | 美商賽吉醫療公司 | 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇 |
| US20200291059A1 (en) | 2017-12-08 | 2020-09-17 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT202100509T1 (it) * | 2013-04-17 | 2021-11-12 | Sage Therapeutics Inc | Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia |
| TW202604538A (zh) * | 2016-08-23 | 2026-02-01 | 美商賽吉醫療公司 | 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇 |
| EP3612186A1 (en) * | 2017-04-18 | 2020-02-26 | Marinus Pharmaceuticals, Inc. | Sustained release injectable neurosteroid formulations |
| EP3678670A1 (en) * | 2017-09-07 | 2020-07-15 | Sage Therapeutics, Inc. | Neuroactive steroids and their methods of use |
| WO2019241442A1 (en) * | 2018-06-12 | 2019-12-19 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof |
| CA3187178A1 (en) | 2020-07-20 | 2022-01-27 | Sage Therapeutics, Inc. | Formulations of 19-nor c3,3- disubstituted c21-n-pyrazolyl steroid and methods of use thereof |
| US20230372364A1 (en) * | 2020-10-01 | 2023-11-23 | Jeremy Hill | Method of treating gaba mediated disorders |
-
2022
- 2022-03-17 JP JP2023554337A patent/JP2024510436A/ja active Pending
- 2022-03-17 WO PCT/US2022/020716 patent/WO2022197901A1/en not_active Ceased
- 2022-03-17 KR KR1020237034937A patent/KR20230158033A/ko active Pending
- 2022-03-17 IL IL305858A patent/IL305858A/en unknown
- 2022-03-17 CA CA3213744A patent/CA3213744A1/en active Pending
- 2022-03-17 MX MX2023010728A patent/MX2023010728A/es unknown
- 2022-03-17 TW TW111109951A patent/TW202300156A/zh unknown
- 2022-03-17 AU AU2022238365A patent/AU2022238365A1/en active Pending
- 2022-03-17 EP EP22715444.0A patent/EP4308162A1/en active Pending
- 2022-03-17 US US18/550,724 patent/US20240245711A1/en active Pending
- 2022-03-17 BR BR112023018607A patent/BR112023018607A2/pt unknown